Gland Pharma Limited (BOM:543245)
India · Delayed Price · Currency is INR 2,820.40
-3.15 (-0.11%)
At close: Aug 21, 2026
Gland Pharma Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 465,091 | 279,443 | 262,358 | 303,932 | 208,882 | 537,705 | |
Market Cap Growth | 45.24% | 6.51% | -13.68% | 45.50% | -61.15% | 32.63% |
Enterprise Value | 434,335 | 250,447 | 236,321 | 286,055 | 175,977 | 508,469 |
Last Close Price | 2820.40 | 1684.56 | 1565.66 | 1792.72 | 1234.72 | 3181.85 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 41.20 | 27.20 | 37.56 | 39.35 | 26.74 | 44.38 |
PS Ratio | 6.92 | 4.35 | 4.67 | 5.37 | 5.76 | 12.22 |
PB Ratio | 4.49 | 2.70 | 2.87 | 3.48 | 2.63 | 7.51 |
P/TBV Ratio | 4.67 | 2.81 | 2.98 | 3.63 | 2.63 | 7.53 |
P/FCF Ratio | 86.03 | 51.69 | 49.48 | 50.08 | 146.03 | 192.42 |
P/OCF Ratio | 45.09 | 27.09 | 28.68 | 30.49 | 57.39 | 68.00 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 6.46 | 3.90 | 4.21 | 5.05 | 4.86 | 11.55 |
EV/EBITDA Ratio | 25.00 | 15.68 | 19.19 | 22.06 | 17.07 | 33.67 |
EV/EBIT Ratio | 33.36 | 21.04 | 27.10 | 29.45 | 19.90 | 36.32 |
EV/FCF Ratio | 80.34 | 46.33 | 44.57 | 47.14 | 123.03 | 181.96 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.03 | 0.04 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.16 | 0.18 | 0.25 | 0.28 | 0.00 | 0.00 |
Debt / FCF Ratio | - | 0.53 | 0.59 | 0.61 | 0.03 | 0.02 |
Net Debt / Equity Ratio | -0.30 | -0.30 | -0.29 | -0.18 | -0.47 | -0.45 |
Net Debt / EBITDA Ratio | -1.79 | -1.93 | -2.14 | -1.21 | -3.64 | -2.15 |
Net Debt / FCF Ratio | - | -5.69 | -4.98 | -2.58 | -26.27 | -11.60 |
Asset Turnover | - | 0.54 | 0.51 | 0.58 | 0.44 | 0.61 |
Inventory Turnover | - | 1.50 | 1.44 | 1.40 | 1.16 | 1.79 |
Quick Ratio | - | 3.41 | 3.01 | 2.61 | 6.58 | 7.80 |
Current Ratio | - | 4.68 | 4.34 | 4.04 | 9.46 | 10.06 |
Return on Equity (ROE) | - | 10.53% | 7.82% | 9.26% | 10.33% | 18.55% |
Return on Assets (ROA) | - | 6.27% | 4.98% | 6.25% | 6.65% | 12.21% |
Return on Invested Capital (ROIC) | 12.72% | 12.11% | 8.39% | 11.67% | 16.14% | 30.73% |
Return on Capital Employed (ROCE) | - | 10.90% | 9.00% | 10.50% | 11.00% | 19.30% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.43% | 3.68% | 2.66% | 2.54% | 3.74% | 2.25% |
FCF Yield | 1.16% | 1.93% | 2.02% | 2.00% | 0.69% | 0.52% |
Dividend Yield | 0.71% | 1.19% | 1.15% | 1.12% | - | - |
Payout Ratio | - | 28.87% | 47.17% | - | - | - |
Buyback Yield / Dilution | -0.14% | -0.13% | -0.01% | -0.03% | -0.09% | -3.96% |
Total Shareholder Return | 0.57% | 1.06% | 1.14% | 1.08% | -0.09% | -3.96% |